Regeneron beats estimates and keeps growing fast

5 November 2020
regeneron-location-big

US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) exceeded analysts’ estimates on both revenue and earnings with its third-quarter financial results.

Revenues rose 32% to $2.29 billion, beating estimates of $2.09 billion, according to IBES data from Refinitiv.

Net profit rose to $842.1 million, or $7.39 per share, in the three months ended September 30, from $669.6 million, or $5.86 per share, a year earlier. Excluding items, Regeneron earned $8.36 per share, beating estimates of $7.14.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology